Abacavir, Dolutegravir, and Lamivudine Film-coated Tablets
Found Under The Trade Name
(Triumeq ®) is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of three drugs with different and complementary mechanisms of action: 600 mg abacavir (reverse transcriptase inhibitor), 50 mg dolutegravir (integrase inhibitor) and 300 mglamivudine (nucleoside analog reverse transcriptase inhibitor).
The drug was developed by ViiV Healthcare and approved by the Food and Drug Administration for use in the United States in August 2014.
Abacavir is a nucleotide reverse transcriptase inhibitor. Specifically, abacavir is a guanosine analogue that interferes with HIV viral RNA-dependent DNA polymerase, ultimately resulting in inhibition of replication of HIV. Dolutegravir inhibits the HIV replication cycle by binding to the integrase active site and inhibiting the strand transfer step of HIV-1 DNA integration. Lamivudine is a cytosine analogue that inhibits HIV reverse transcription by terminating the viral DNA chain.
Adverse Effects
The following adverse reactions were reported in <2% of patients.[2]
Central nervous system: drowsiness, lethargy, nightmares, sleep disorders, suicidal ideation
Dermatologic: pruritis
Endocrine and metabolic: hypertriglyceridemia
Gastrointestinal: abdominal distention, abdominal distress, abdominal pain, anorexia, dyspepsia, flatulence, gastroesophageal reflux disease, upper abdominal pain, vomiting
Hepatic: hepatitis
Neuromuscular and skeletal: arthralgia, myositis
Renal: renal insufficiency
Miscellaneous: fever
See individual agents as well as other combination products for additional information.
Pregnancy
Triumeq is pregnancy category C as there are no adequate and well-controlled trials in pregnant women. However, reproduction studies with the components of Triumeq have been performed in animals. Triumeq should only be used in pregnancy if the potential benefits outweigh the risks.To monitor maternal-fetal outcomes of pregnant women that have used an antiretroviral, including Triumeq, an Antiretroviral Pregnancy Registry has been established.
Breastfeeding
The Centers for Disease Control and Prevention (CDC) recommend that HIV-infected mothers do not breastfeed their infants to avoid risking postnatal transmission of HIV. This recommendation is coupled with the potential for serious adverse reactions in nursing infants. Dolutegravir and abacavir were shown to be excreted in the milk of lactating rats. Lamivudine was shown to be excreted in human breast milk.
Found Under The Trade Name
(Triumeq ®) is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of three drugs with different and complementary mechanisms of action: 600 mg abacavir (reverse transcriptase inhibitor), 50 mg dolutegravir (integrase inhibitor) and 300 mglamivudine (nucleoside analog reverse transcriptase inhibitor).
The drug was developed by ViiV Healthcare and approved by the Food and Drug Administration for use in the United States in August 2014.
Abacavir is a nucleotide reverse transcriptase inhibitor. Specifically, abacavir is a guanosine analogue that interferes with HIV viral RNA-dependent DNA polymerase, ultimately resulting in inhibition of replication of HIV. Dolutegravir inhibits the HIV replication cycle by binding to the integrase active site and inhibiting the strand transfer step of HIV-1 DNA integration. Lamivudine is a cytosine analogue that inhibits HIV reverse transcription by terminating the viral DNA chain.
Adverse Effects
The following adverse reactions were reported in <2% of patients.[2]
Central nervous system: drowsiness, lethargy, nightmares, sleep disorders, suicidal ideation
Dermatologic: pruritis
Endocrine and metabolic: hypertriglyceridemia
Gastrointestinal: abdominal distention, abdominal distress, abdominal pain, anorexia, dyspepsia, flatulence, gastroesophageal reflux disease, upper abdominal pain, vomiting
Hepatic: hepatitis
Neuromuscular and skeletal: arthralgia, myositis
Renal: renal insufficiency
Miscellaneous: fever
See individual agents as well as other combination products for additional information.
Pregnancy
Triumeq is pregnancy category C as there are no adequate and well-controlled trials in pregnant women. However, reproduction studies with the components of Triumeq have been performed in animals. Triumeq should only be used in pregnancy if the potential benefits outweigh the risks.To monitor maternal-fetal outcomes of pregnant women that have used an antiretroviral, including Triumeq, an Antiretroviral Pregnancy Registry has been established.
Breastfeeding
The Centers for Disease Control and Prevention (CDC) recommend that HIV-infected mothers do not breastfeed their infants to avoid risking postnatal transmission of HIV. This recommendation is coupled with the potential for serious adverse reactions in nursing infants. Dolutegravir and abacavir were shown to be excreted in the milk of lactating rats. Lamivudine was shown to be excreted in human breast milk.
